Key TakeawaysEli Lilly has joined Johnson & Johnson in filing a lawsuit against the federal government over a decades-old drug discounting program.The companies have said the 340B program, which requires drugmakers to sell discounted medications to certain medical facilities, needs changes.The Health Resources and Services Administration, however, has rejected the companies' proposed changes to the program. Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting t ...

SURMOUNT-1 results show a 94% reduction in risk of progression to type 2 diabetes across all pooled doses of tirzepatide compared to placebo over three yearsResults suggest one new case of diabetes could be prevented for every nine patients treated with tirzepatideParticipants treated with tirzepatide had an average weight reduction of 22.9% (15 mg dose)INDIANAPOLIS, Nov. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study ...

If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.Finding stocks that could quickly double or triple your money isn't hard. Just about every day, a Wall Street analyst issues a price target that suggests a relatively small and unestablished company could double or triple your money. Usually, though, the word "could" is working way too hard for such a risky investment to make sense for most investors.If you want to avoid the riskiest corners of the stock ...

RISES OVER 1.6% AT IT’S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNALEli Lilly & Company LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. Today, at 10:35 AM on November 12th, a significant trading signal occurred for Eli Lilly as it demonstrated a Power Inflow at a price of $816.14. This indicator is crucial for traders who want to know directionally where institutions and so-calle ...

Core Insights - Eli Lilly and Company (LLY) has experienced a 10.6% decline in stock price this month following disappointing third-quarter results, missing both earnings and sales estimates while lowering financial guidance for the year [1][2] Financial Performance - The total revenue guidance was narrowed from a range of $45.4 billion to $46.6 billion down to $45.4 billion to $46.0 billion, and earnings per share guidance was sharply cut from $16.10 to $16.60 to $13.02 to $13.52 due to IPR&D charges related to the acquisition of Morphic [2] - Despite the disappointing sales performance, Lilly's revenues were up 42% on an organic basis in the third quarter, with a projected year-over-year revenue growth of 50% in the fourth quarter [21] Product Performance - Mounjaro and Zepbound, key drugs for diabetes and obesity, generated sales of $11.0 billion in the first three quarters of 2024, accounting for approximately 45% of total revenues [6] - Sales of Mounjaro and Zepbound were impacted by inventory issues, with channel inventory decreasing at wholesalers in the third quarter [7] - Lilly is balancing demand and supply for these drugs and expects increased demand activities in the fourth quarter, which should benefit sales in 2025 [8] Competitive Landscape - Lilly's tirzepatide medicines face strong competition from Novo Nordisk's semaglutide products, which have also missed estimates for earnings and sales [10] - Other companies like Amgen and Viking Therapeutics are developing GLP-1-based candidates that could pose future competition to Mounjaro and Zepbound [11] Pipeline and Future Prospects - Lilly has received approvals for several new drugs, including Kisunla for Alzheimer's disease, and is investing in obesity treatments with 11 new molecules in clinical development [12][14] - The company is also developing tirzepatide for additional indications, which could further boost sales [9] Stock Performance and Valuation - Lilly's stock has risen 42.7% this year, outperforming the industry and the S&P 500 [15] - The stock is currently trading at a premium to the industry, with earnings estimates for 2024 declining from $15.80 to $13.19 per share over the past 30 days [17][18] Investor Sentiment - Despite recent declines, the company still has growth prospects as demand for Mounjaro and Zepbound remains strong, suggesting investors may consider holding the stock [22]

Conditions are getting a bit more challenging for the drugmaker.If you looked solely at its stock price, you might get the idea that Eli Lilly (LLY 4.28%) is having a bit of an off quarter. Over the past 30 days, its shares fell by about 10%, though they are still up by around 37% so far this year. And, if management is correct, one cloudy trend driving their recent decrease in performance is more likely to stick around than shareholders would prefer.Nonetheless, things aren't anywhere near as bad as they m ...

The good times aren't over, but the peak of the party might be passing.Eli Lilly (LLY 4.28%) and Novo Nordisk (NVO -0.40%), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both declined even as the rest of the market rose.Short-term price changes shouldn't have anything to do with an investment thesis for either stock. Still, investors sold shares in both for a reason. And there's a chance that the issue driving ...

The market's perception of the pharmaceutical company has undeniably shifted.Even a juggernaut like Eli Lilly (LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, signaling that the market's reception to its financial performance was strongly negative.Shareholders discovered that there's reason to believe that a previously hypothesized risk is now real and that it presents a possible threat to ...

Eli Lilly stock has fallen in the days following the release of its latest earnings numbers.If you're investing in a stock with a high valuation, you know that expectations are going to be high when it's time for the company to report earnings. Any miss compared to analyst estimates or underwhelming guidance can quickly lead to a sell-off, analyst downgrades, and a much different outlook for the stock as a whole.Healthcare giant Eli Lilly (LLY -3.68%) has been trading at an inflated valuation for some time ...

Eli Lilly’s NYSE: LLY market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a rally because of underperformance, but the salient details are that growth is robust, driving impressive profits, and is expected to accelerate in 2025. The net result from the release is that analysts are raising their estimates for Q4, next year, and the next five year’s earnings, creating a tailwind for the LLY market.   Eli Lilly and Company TodayLLYEli Lilly and Company$806.14 -12 ...